Combining drugs to improve cancer treatment outcomes
Official title: Targeting the PNP - SAMHD1 synthetic-lethal combination in cancer
Funded at Albert Einstein College of Medicine · NIH-11088272 · Data updated 2026-11-12
This study is exploring a new way to treat certain tough-to-treat cancers by using a drug called Forodesine along with another treatment that targets a specific enzyme, hoping to make the therapy work better for patients with resistant T-cell lymphoma.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project start | May 13, 2024 |
| Project end | April 30, 2029 |
| Funding year | 2025 |
| Award (this year) | $603,347 |
| NIH project number | 5R01CA290537-02 |
| Project ID | NIH-11088272 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with refractory or relapsed peripheral T-cell lymphoma who have not responded to standard treatments.
✕Less likely to help
Patients with cancer types other than T-cell lymphoma or those who have not been diagnosed with refractory disease may not benefit from this research.
What this research studies
This research investigates a new approach to cancer treatment by targeting specific enzymes involved in cancer cell survival. It focuses on the combination of a drug called Forodesine, which has shown promise in treating certain types of T-cell lymphoma, with inhibitors of another enzyme, SAMHD1, to enhance the drug's effectiveness. By understanding how these enzymes interact, the research aims to develop a more effective therapy for patients with resistant cancer types. Patients may benefit from this innovative combination therapy that could lead to improved remission rates.
Why it matters
Potential benefit: If successful, this research could provide a more effective treatment option for patients with refractory T-cell lymphomas.
How similar studies have gone: Previous studies have shown success with Forodesine in treating refractory T-cell lymphoma, indicating that this combination approach may also yield positive results.
Where this research is happening
-
Albert Einstein College of Medicine
Bronx, United States Active
Researchers
- Principal investigator: Schramm, Vern L. — Albert Einstein College of Medicine
- Study coordinator: Schramm, Vern L.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.